BESTASB., MCCLOREYG., TEDEBARKU., MORENOP.M.D., ROBERTST.C., HAMMONDS.M., SMITHC.I.E., WOODM.J.A., and EL ANDALOUSSIS. (2013). Design and application of bispecific splice switching oligonucleotides. Nucleic Acid Ther., 24, 13–24.
2.
EVERSM.M., TRANH.D., ZALACHORASI., MEIJERO.C., DEN DUNNENJ.T., VAN OMMENG.J., AARTSMA-RUSA., and VAN ROON-MOMW.M. (2013). Preventing formation of toxic n-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification. Nucleic Acid Ther., 24, 4–12.
3.
FALZARANOM.S., PASSARELLIC., and FERLINIA. (2014). Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy. Nucleic Acid Ther., 24, 87–100.
4.
JARVERP., O'DONOVANL., and GAITM.J. (2013). A chemical view of oligonucleotides for exon skipping and related drug applications. Nucleic Acid Ther., 24, 37–47.
5.
JIRKAS.M., HEEMSKERKH., TANGANYIKA-DE WINTERC.L., MUILWIJKD., PANGK.H., DE VISSERP.C., JANSONA., KARNAOUKHT.G., VERMUER., ‘T HOENP.A.et al. (2013). Peptide conjugation of 2’-O-methyl phosphorothioate antisense oligonucleotides enhances cardiac uptake and exon skipping in mdx mice. Nucleic Acid Ther., 24, 25–36.
6.
KOOT., and WOODM.J. (2013). Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. Hum. Gene Ther., 24, 479–488.
7.
MUNTONIF. (2010). The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009. Neuromuscul. Disord., 20, 355–362.
8.
SIVAK., COVELLO, G., and DENTIM.A. (2014). Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases. Nucleic Acid Ther., 24, 69–86.
9.
SPITALIP., and AARTSMA-RUSA. (2012). Splice modulating therapies for human disease. Cell, 148, 1085–1088.
10.
VAN ROON-MOMW.M., and AARTSMA-RUSA. (2012). Overview on applications of antisense-mediated exon skipping. Methods Mol. Biol., 867, 79–96.
